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Summary There is increasing concern that contraceptive pill usage may increase the risk of hepatocellular
carcinoma. As primary malignant liver cancer is very rare in this country, any effect due to oral
contraceptives should be apparent in national mortality statistics. An analysis of mortality rates over the last
24 years shows a small but consistent increase for young women starting to occur during the end of the last
decade. However no such trend is apparent in data from other countries where pill usage is comparable to
that in the U.K. Overall liver cancer remains an extremely uncommon cause of death in developed countries,
but it will be particularly important to monitor trends in this disease in the future.
An association between the use of contraceptive
steroids and the development of benign diseases of
the liver was first suggested by Baum et al. (1973).
Since then there have been many reports of such an
association (W.H.O., 1978) and there is now firm
evidence (Mettlin & Natarajan, 1981) that the use
of oral contraceptives increases the incidence of
benign liver tumours and particularly of
hepatocellular adenomas. Two case-control studies
have been carried out (Edmondson et al., 1976;
Rooks et al., 1979) and both indicate that the
relative, although not the absolute, increase in risk
attributable to the pill is gross. The results of the
larger series (Rooks et al., 1979) suggested that the
overall risk of these very rare tumours was
increased more than 100 fold after 3 years usage
and that the risk was markedly modified by age,
duration of use, and the dose of steroid in the pill.
Evidence that oral contraceptives might also
produce malignant hepatic carcinomas is
accumulating slowly. Anecdotal reports of this
disease in young women taking the pill are
becoming numerous (summarised in Shar & Kew,
1982; Gala & Griffen, 1983). In addition, surveys of
tumour registries (Christopherson et al., 1978; Vana
et al., 1977) have shown high proportions of pill
users amongst cases of primary malignant liver
cancer. These findings are liable to be affected by
selective bias in reporting; but the validity of the
association is suggested by the observation of
clinical differences between the cases reported in pill
users and other women (Klatskin, 1977; Neuburger
et al., 1980) and the occasional progression of a
pill-associated hepatic adenoma to carcinoma
(Davis et al., 1975; Klatskin, 1977). Experiments on
rats have shown significant numbers of malignant
liver tumours induced by contraceptive steroids
(Committee on Safety of Medicines, 1972) and
there is evidence that such steroids could act as
initiators (Committee on Safety of Medicines,
1972), activators of carcinogens (Aldercreutz &
Tenhunen 1970) or promoters (Wanless & Medline,
1982; Yarger & Yarger, 1980).
Recently, Henderson et al. (1983) reported a
study comparing contraceptive use by young
women suffering from hepatocellular carcinoma
with that among age-matched neighbourhood
controls. All 11 affected women had used steroids,
the average duration of use being 65.5 months,
while only 13/22 control women had done so, with
an average duration of use of 27.1 months. These
differences were both statistically highly significant.
There are thus strong suggestions that oral
contraceptive use may cause malignant liver
tumours. However, such tumours are very rare in
western countries, especially in young women. If
O.C. pill usage were affecting the incidence of the
disease, then a trend might be expected to emerge
in national mortality statistics in the years
subsequent to the introduction of the pill. We have
therefore examined the mortality rates for
malignant neoplasms of the liver in England and
Wales over the past 24 years.
Materials and methods
National death certification rates for England and
Wales from cancer diagnosed as having its primary
site in liver cells or in intrahepatic bile ducts were
examined for the years 1958 (the first year in which
liver neoplasms were separated from those of the
gall bladder and extrahepatic bile ducts in national
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mortality statistics) to 1981 (the last year for which
detailed figures were available). Table I shows the
age standardised rates for each sex and for the four
age groups 20-29, 30-39, 40-49 and 50-54 years.
Women above the age of 55 were excluded partly
because they are unlikely to have had any
substantial exposure to the pill and partly because
mis-diagnosis of secondary liver cancers as primary
(and, to a less extent, vice versa) increases sharply
with age (Zaridze & Doll, unpublished) and this
might tend to obscure any real trend in mortality at
older ages.
Results and discussion
Overall, the total number of deaths certified as
attributable to primary malignant liver cancer
below the age of 55 is very small, being only about
100 per year for the combined sexes. This presents
-0.2% of all deaths and 0.6% of all cancer deaths
in the age-range 20-54 years. The natural
variability of such small numbers means that there
are likely to be marked fluctuations in rates from
year to year. This, with no particular pattern
apparent, is what is observed among the male
Table IA Annual age-standardised1 mortality rates per 106 population
for primary liver cancer2, England and Wales, 1958-1981 (Nos. of
deaths in parentheses).
Females 20-29 30-39 40-49 50-54
1958 0.7 (2) 0.9 (3) 4.6 (15) 4.3 (7)
1959 0.7 (2) 2.0 (7) 4.0 (13) 7.4 (12)
1960 1.1 (3) *2.5 (8) 3.7 (12) 8.6 (14)
1961 0.7 (2) 1.2 (4) 5.0 (16) 9.2 (15)
1962 0.3 (1) 2.2 (7) 5.0 (16) 4.9 (8)
1963 0.7 (2) 1.0 (3) 3.2 (10) 4.3 (7)
1964 0.7 (2) 1.4 (4) 2.8 (9) 3.0 (5)
1965 0.3 (1) *3.1 (9) 4.4 (14) 4.3 (7)
1966 0.0 (0) 1.4 (4) *6.5 (20) 6.8 (11)
1967 0.3 (1) 1.0 (3) 2.2 (7) 5.1 (8)
1968 *1.8 (6) 2.1 (6) 4.7 (15) 9.4 (14)
1969 *1.2 (4) 0.4 (1) 5.0 (16) *11.2 (16)
1970 0.6 (2) 1.4 (4) 3.7 (12) *10.4 (15)
1971 1.2 (4) 1.8 (5) 3.3 (10) 7.4 (11)
1972 0.3 (1) 0.7 (2) 4.7 (14) 5.8 (9)
1973 0.0 (0) 1.1 (3) *5.4 (16) 9.9 (16)
1974 0.6 (2) 0.7 (2) 3.5 (10) 7.2 (12)
1975 0.9 (3) 2.0 (6) 3.5 (10) *13.2 (21)
1976 0.6 (2) 2.2 (6) 1.8 (5) 9.1 (14)
1977 *1.5 (5) *2.7 (8) *5.4 (15) 4.0 (6)
1978 *1.5 (5) 2.3 (7) 3.2 (9) 6.2 (9)
1979 0.9 (3) *2.6 (8) *6.5 (18) 7.6 (11)
1980 *2.1 (7) *3.3 (11) 5.1 (14) *13.3 (19)
1981 0.6 (2) 1.1 (4) *5.4 (15) *11.2 (16)
*Indicates the 5 years with the highest age- and sex-specific rates for
the 24-year period.
1Standardised for age by taking the average of the corresponding
quinquennial rates for the age-ranges 20-24, 25-29, etc. to 50-54. (N.B.
This happens to be equivalent, for these particular age-groups, to
standardisation using the European or the World standard populations
(Waterhouse et al., 1976) in each age range).
2Defined using the following ICD codings:
7th revision (1958-67) 155.0
8th revision (1968-78) 155.0, 155.1 (155)
9th revision (1979-81) 155.0, 155.1
Sources: Registrar General. Statistical Reviews of England and Wales.
London: HMSO 1958-1973. Office of Population Censuses & Surveys.
Mortality Statistics-cause, England and Wales. Series DH2 nos. 1-7,
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Table IB Annual age-standardised1 mortality rates per 106 population
for primary liver cancer2, England and Wales, 1958-1981 (Nos. of
deaths in parentheses).
Males 20-29 30-39 40-49 50-54
1958 1.1 (3) 2.8 (9) 5.7 (18) 16.2 (25)
1959 1.4 (4) 1.5 (5) 5.6 (17) 13.5 (21)
1960 0.4 (1) 3.5 (11) 6.0 (19) 16.0 (25)
1961 0.3 (1) *3.6 (11) 6.7 (21) 15.9 (25)
1962 1.7 (5) 1.6 (5) 6.4 (20) 13.4 (21)
1963 0.7 (2) *5.2 (16) 6.4 (20) 13.5 (21)
1964 *2.0 (6) 3.3 (10) 9.1 (28) 12.2 (19)
1965 1.0 (3) 1.7 (5) 6.1 (19) 16.8 (26)
1966 1.0 (3) 0.7 (2) *9.8 (30) 17.7 (27)
1967 1.2 (4) *4.0 (12) 7.6 (24) 14.1 (21)
1968 0.9 (3) 1.3 (4) 8.2 (26) *30.5 (43)
1969 1.0 (3) 2.7 (8) 7.2 (23) *25.7 (35)
1970 1.1 (4) 2.0 (6) 8.5 (27) 20.2 (28)
1971 *2.0 (7) *3.9 (11) 3.6 (11) 16.2 (23)
1972 1.1 (4) 1.4 (4) 6.4 (19) *21.7 (32)
1973 0.8 (3) 1.4 (4) *9.2 (27) *21.3 (33)
1974 1.1 (4) 3.0 (9) 4.5 (13) 20.6 (33)
1975 *2.0 (7) 2.6 (8) 8.4 (24) 12.3 (19)
1976 0.3 (1) 1.4 (4) 5.7 (16) 18.0 (27)
1977 0.9 (3) 2.3 (7) 8.9 (25) 15.1 (22)
1978 1.4 (5) *4.7 (15) 6.7 (19) 14.7 (21)
1979 1.4 (5) 3.5 (11) *11.7 (33) *22.0 (31)
1980 1.4 (5) 1.5 (5) *10.7 (30) 18.7 (26)
1981 *2.6 (9) 3.3 (11) *11.4 (32) 16.3 (23)
*Indicates the 5 years with the highest age- and sex-specific rates for
the 24-year period. (4 highest years for 20-29 age group).
'Standardised for age by taking the average of the corresponding
quinquennial rates for the age-ranges 20-24, 25-29, etc. to 50-54. (N.B.
This happens to be equivalent, for these particular age-groups, to
standardisation using the European or the World standard populations
(Waterhouse et al., 1976) in each age range).
2Defined using the following ICD codings:
7th revision (1958-67) 155.0
8th revision (1968-78) 155.0, 155.1 (155)
9th revision (1979-81) 155.0, 155.1
Sources: Registrar General. Statistical Reviews of England and Wales.
London: HMSO 1958-1973. Office of Population Censuses & Surveys.
Mortality Statistics-cause, England and Wales. Series DH2 nos. 1-7,
London, HMSO 1974-1981.
deaths (Table IB), the fluctuations occurring over
the whole of the time period considered (with
sporadic clusters of high rates in the last 3 years for
the 40-49 age group and in 1968-1970 for the 50-
54 age group).
By contrast, among the female deaths (Table IA),
there does appear to be a slight systematic increase
in the mortality rates towards the end of the 1970s.
This increase is most noticeable among the younger
age groups. For each of the age groups 20-29, 30-
39 and 40-49 the last 5 years have seen 3 of the 5
B.J.C.- B
highest annual incidence rates in the entire 24-year
period. It is difficult to interpret the results of any
statistical test for trend in these data as the
significance of the test will depend heavily on the
year chosen as the starting point. If, however, one
aggregates the two youngest and the two oldest age
groups and compares the mortality rate for the last
6 years with that in the previous six (Table II), it
appears that there has been a significant increase
for younger women (P<0.005) but not for older
women or for either age group in men.352 D. FORMAN et al.
Table II Comparison of age-standardised death rates
from primary liver cancer between the years 1970-75 and
1976-81, for England and Wales.
Death ratesper 106 (population at risk-millions)
1970-75 1976-81 x2 (M.H.) P
Females
20-39 0.9 (38.02) 1.8 (39.81) 10.08 <0.005
40-54 5.7 (27.08) 5.9 (25.43) 0.12 N.S.
Males
20-39 1.9 (38.99) 2.0 (40.79) 0.33 N.S.
40-54 10.7 (26.73) 11.9 (25.50) 1.68 N.S.
N.S. =not signifcant
The pill was introduced in England and Wales in
the early 1960s and became common by the middle
of that decade. In view of the long induction period
that is commonly observed in human cancers.
attributable to chemicals, any carcinogenic effects
attributable to the pill might be seen only after a
substantial number of women had been exposed for
10-15 years i.e. towards the end of the 1970s. This
is the pattern that has actually been observed. It
might also be expected that any real effects would
be more noticeable amongst women aged <40
years, for such women are likely to have been more
heavily exposed to the pill, and, moreover, their
very low rates of liver cancer before introduction of
the pill should enable small absolute increases to be
detected.
The data in Table I lend some support to the
idea that oral contraceptives may have caused some
cases of liver carcinoma, although the very low
mortality figures among young women in 1981
(only 6 deaths for the 20-39 age group) suggest
that the apparent trends among such women during
the late 1970s may have been produced at least in
part by the random fluctuation of small numbers.
If the increase in mortality is genuine, and due to
a carcinogenic effect of the pill, similar trends
should be apparent in other countries where the
incidence of the disease is also normally low and
pill consumption is equivalent to that in England
and Wales. Four countries where this is the case are
Australia, the United States, West Germany and
the Netherlands which in 1975 had about 29, 16, 28
and 40% respectively, of women under 44 years on
the pill compared with 20% in the UK (Population
Reports, 1982). Corresponding triennial mortality
rates for these 4 countries are given in Table III
with the England and Wales figures for
comparison. Although they do not extend until
1981, it is clear that in these countries there was no
sign of the trends which were already evident by
1978 in young women in England and Wales. (The
fluctuations seen in the data from Australia and the
Netherlands probably reflect the smaller
populations in these countries). Although there are
certainly many possibilities for error in the
allocation of deaths to liver tumours on death
certificates it is remarkable that the rates recorded
in the 5 countries in Table III are so similar. This
similarity and our personal experience of the
validity of the diagnosis, at least in youth and early
middle age, suggests that in most developed
countries such data will be reasonably trustworthy.
The evidence at present is therefore indecisive. If
the risk of hepatocellular carcinoma associated with
pill usage were as large as suggested by Henderson
et al. (1983), then a clear increase in national
mortality rates would be expected among young
women. The only country of those considered
where there is a suggestion of this, however, is
England and Wales, which tends to suggest that
any real effects must be either small or slow to
appear. Moreover, even if the British figures were
indicative of a real pill-related trend, the absolute
risk of pill-induced liver carcinomas must still be
small, probably involving no more than 10 deaths a
year in the whole country among (in 1975) some
3.5 million users (Wiseman & Macrae, 1981). But, a
risk that is small after only a few years of exposure
may become substantial later; also, in countries
where other risk factors (e.g. chronic active
hepatitis B infection or aflatoxin contamination)
are widespread the absolute risks may be much
larger.
Apart from oral contraceptives (sales of which in
Britain increased from 13 million packs in 1970 to
26 million packs in 1980), there are many other
factors that might affect liver cancer trends: use of
alcohol is increasing and parts of the growing
homosexual community appear to be at unusual
risk of hepatitis B transmission (as are some drug
abusers). Also, among the plethora of chemicals
that have come into widespread use during the past
half century, there are many that can be oxidised
more readily by the liver than by any other organ
into highly reactive species (which is presumably
why so many of the chemicals that have been found
to cause cancer in animals affect the liver). In view
of all this, it is somewhat reassuring that liver
cancer remains such an uncommon cause of death
in developed countries, and that clear increases are
not generally apparent. These various factors,
however, make it particularly important to continue
to monitor trends in liver cancer mortality, as well
as to monitor the causes of the disease directly.
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Table Ill Triennial age-standardised1 death certification rates per 106 population for primary
liver cancer2 in England and Wales, USA, Australia, West Germany, and the Netherlands.
1967-69 to 1979-81.
England The
& Wales USA Australia W. Germany Netherlands
Females 20-39
1967-693 1.1 1.4 0.6 1.0 0.7
1970-72 1.0 1.5 1.9 0.8 1.2
1973-75 0.9 1.3 0.7 0.9 1.3
1976-78 1.8 1.3 1.6 0.9 1.0
1979-814 1.8 1.5 N/A N/A N/A
Females 40-54
1967-693 5.5 6.3 6.2 7.5 5.7
1970-72 5.2 6.2 6.6 8.9 5.2
1973-75 6.1 5.9 4.5 8.1 10.3
1976-78 4.5 6.7 6.5 7.3 4.7
1979-814 7.4 6.6 N/A N/A N/A
Males 20-39
1967-693 1.8 1.4 1.0 1.2 1.4
1970-72 1.9 2.1 2.7 1.5 1.1
1973-75 1.8 1.8 1.1 1.1 1.9
1976-78 1.8 1.9 2.1 1.3 2.9
1979-814 2.3 2.0 N/A N/A N/A
Males 40-54
1967-693 12.9 13.8 12.6 12.2 17.2
1970-72 10.6 12.3 14.4 13.8 11.8
1973-75 10.9 11.6 9.1 14.9 14.1
1976-78 10.0 13.7 14.0 14.1 13.6
1979-814 13.9 12.0 N/A N/A N/A
N/A=not available
'Standardisation as for England and Wales rates in Table I, then 3 years averages calculated.
2Defined as in Table I.
3Figures for USA, Australia, and West Germany for 1968 and 1969 only.
Figures for the Netherlands for 1969 only.
4Figures for USA for 1979 only. The lack of data for Australia, West Germany, and the
Netherlands in this period is due to the introduction of the 9th revision ICD coding which
combines the category "liver cancer, unspecified primary or secondary" within the 155 rubric.
This means that for countries which only publish data using 3-digit ICD classifications, it is
impossible to compare rates from primary liver cancer beyond the periods when the 8th revision
ceased being used.
Sources: England and Wales-as in Table I.
USA-Deaths "Vital statistics of the United States: Volume II; Mortality (Part A) US Govt.
Printing Office, Washington D.C. 1968-1978, Deaths for 1979 and Populations-Personal
communication from US Bureaus of the census. Populations correlated for census undercount
as in Doll & Peto (1981), Appendix B.
Australia-"Australia-Causes of Death" Commonwealth Bureaus of Census and Statistics,
Canberra 1968-73. "Causes of Death-Australia" Australian Bureaus of Statistics, Canberra
1974-1978.
West Germany-Deaths "Gesundheitswesen-Reihe 4-Todesurachen" Populations-
"Statistics Jahrbuch fur die Bundesrepublik Deutschland. 1968-1978 Statistics Bundesamt,
Wiesbaden.
Netherlands-Deaths "Netherlands-causes of death", Populations "Statistical Yearbook of
the Netherlands" 1969-1978 Netherlands Central Bureau of Statistics.354 D. FORMAN et al.
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